Base de dados : LILACS
Pesquisa : D02.455.426.559.389.703 [Categoria DeCS]
Referências encontradas : 24 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 24 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1153964
Autor: Marta, Guilherme Nader; da Fonseca, Leonardo G; Braghiroli, Maria Ignez; Moura, Fernando; Hoff, Paulo M; Sabbaga, Jorge.
Título: Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
Fonte: Clinics;76:e2498, 2021. tab, graf.
Idioma: en.
Resumo: OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. Patients were divided into two groups, Group A, individuals <70 years of age, and Group B, individuals 70 years of age or older at the time of treatment initiation. Efficacy, measured based on overall survival (OS) and time to treatment failure (TTF), and toxicity were compared between groups. RESULTS: A total of 238 patients with advanced HCC who received sorafenib between 2007 and 2018 were evaluated. The median age for Group A was 59.1 years and that for Group B 73.6 years. The major prognostic characteristics were balanced between the groups. There were no significant differences in OS between Group A (8.0 months, 95%CI 6.34-9.3) and Group B (9.0 months, 95%CI 5.38-12.62), p=0.433, or in TTF between Group A (3.0 months, 95%CI 2.39-3.60) and Group B (3.0 months, 95%CI 1.68-4.32), p=0.936. There were no significant differences between Groups A and B with respect to the incidence of adverse events or treatment discontinuation because of toxicity. CONCLUSION: Efficacy and safety of sorafenib did not differ significantly between younger and older patients with HCC. Our data suggest that age alone should not restrict clinical decision-making for patients with advanced HCC.
Descritores: Carcinoma Hepatocelular/tratamento farmacológico
Neoplasias Hepáticas/tratamento farmacológico
Antineoplásicos/efeitos adversos
-Compostos de Fenilureia/efeitos adversos
Prognóstico
Niacinamida/efeitos adversos
Sorafenibe/efeitos adversos
Limites: Humanos
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  2 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887229
Autor: Varghese, Joy; Kedarisetty, Chandan Kumar; Venkataraman, Jayanthi; Srinivasan, Vijaya; Deepashree, Thiruchunapalli; Uthappa, Mangerira Chinnappa; Ilankumaran, Kaliamurthy; Govil, Sanjay; Reddy, Mettu Srinivas; Rela, Mohamed.
Título: Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience
Fonte: Ann. hepatol;16(2):247-254, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background & Aim. Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. We studied the role of combination of TACE and sorafenib in BCLC stages B/C. Material and methods. We undertook an observational study on a cohort of cirrhotics with HCC from August 2010 through October 2014. Patients in BCLC stages B/C who had received TACE and/or sorafenib were included. mRECIST criteria were used to assess tumor response. The primary end point was overall survival. Results. Out of 124 patients, 47.6% were in BCLC-B and 52.4% in BCLCC. Baseline characteristics were comparable. The predominant etiology was cryptogenic (37.2% and 38.5%, p = NS). 49.1% in BCLC-B and 56.9% in BCLC-C had received TACE+sorafenib. In BCLC-B, the overall survival improved from 9 months (95% CI 6.3-11.7) using TACE only to 16 months (95% CI 12.9-19.1) using TACE+sorafenib (p < 0.05). In BCLC-C, addition of TACE to sorafenib improved the overall survival from 4 months (95%CI 3-5) to 9 months (95%CI 6.8-11.2) (p < 0.0001). As per mRECIST criteria, patients on TACE+sorafenib had reduced progressive disease (37.8% vs. 83.3%), improved partial response (43.2% vs. 3.3%) and one had complete response compared to those on sorafenib alone (p < 0.0001) in BCLC-C but not in BCLC-B group. Hand foot syndrome was noted in 27.7% patients on sorafenib and post TACE syndrome in 80.2% patients, but both were reversible. No major adverse events were noted. Conclusion. TACE+sorafenib was more effective than TACE or sorafenib alone in HCC BCLC stages B or C with a significant survival benefit and improved tumour regression especially in BCLC-C patients.
Descritores: Compostos de Fenilureia/uso terapêutico
Niacinamida/análogos & derivados
Carcinoma Hepatocelular/terapia
Inibidores de Proteínas Quinases/uso terapêutico
Neoplasias Hepáticas/terapia
Antineoplásicos/uso terapêutico
-Compostos de Fenilureia/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
Quimioembolização Terapêutica/efeitos adversos
Quimioembolização Terapêutica/mortalidade
Niacinamida/efeitos adversos
Niacinamida/uso terapêutico
Carcinoma Hepatocelular/etiologia
Carcinoma Hepatocelular/mortalidade
Carcinoma Hepatocelular/patologia
Inibidores de Proteínas Quinases/efeitos adversos
Carga Tumoral
Estimativa de Kaplan-Meier
Neoplasias Hepáticas/etiologia
Neoplasias Hepáticas/mortalidade
Estadiamento de Neoplasias
Antineoplásicos/efeitos adversos
Limites: Humanos
Responsável: BR1.1 - BIREME


  3 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887230
Autor: Carvalho, Sandra R. Almeida; Ferraz, Maria L. Gomes; Matos, Carla A. Loureiro; Silva, Antônio E. Benedito; Carvalho Filho, Roberto J; Perez, Rogério Renato; Gonzalez, Adriano Miziara; Salzedas-Netto, Alcides A; Szejnfeld, Denis; D'Ippolito, Giuseppe; Lanzoni, Valéria Pereira; Silva, Ivonete S. Souza.
Título: Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil
Fonte: Ann. hepatol;16(2):255-262, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background. Hepatocellular carcinoma (HCC) is the most common malignancy that develops in cirrhotic livers. Its clinical and epidemiological characteristics and mortality rates vary according to geographical region. The objective of this study was to evaluate the clinical profile, epidemiological characteristics, laboratory parameters, treatment and survival of patients with HCC. Material and methods. Patients with HCC seen between 2000 and 2012 were studied. The Kaplan-Meier method was used for survival analysis according to variables in question. Results. The study included 247 patients with a mean age of 60 ± 10 years. There was a predominance of males (74%). The main etiologies of HCC were HCV infection (55%), excessive alcohol consumption (12%), and HBV infection (8%). Liver cirrhosis was present in 92% of cases. The mean tumor number and diameter were 2 and 5 cm, respectively. Patients meeting the Milan criteria corresponded to 43% of the sample. Liver transplantation was performed in 22.4% of patients of the Milan subset and in 10% of the whole sample. The overall mean survival was 60 months, with a 1-, 3- and 5-year survival probability of 74%, 40% and 29%, respectively. Lower survival was observed among patients with alcoholic etiology. Survival was higher among patients submitted to liver transplantation (P < 0.001), TACE (P < 0.001), or any kind of treatment (P < 0.001). However, no difference was found for surgical resection (P = 0.1) or sorafenib (P = 0.1). Conclusion. Patients with HCC were mainly older men diagnosed at an advanced stage. Treatment was associated with better overall survival, but few patients survived to be treated.
Descritores: Transplante de Fígado
Quimioembolização Terapêutica
Carcinoma Hepatocelular/terapia
Técnicas de Ablação
Hepatectomia
Neoplasias Hepáticas/terapia
Antineoplásicos/uso terapêutico
-Compostos de Fenilureia/uso terapêutico
Fatores de Tempo
Brasil/epidemiologia
Fatores de Risco
Resultado do Tratamento
Quimioembolização Terapêutica/efeitos adversos
Quimioembolização Terapêutica/mortalidade
Niacinamida/análogos & derivados
Carcinoma Hepatocelular/etiologia
Carcinoma Hepatocelular/mortalidade
Carcinoma Hepatocelular/patologia
Carga Tumoral
Estimativa de Kaplan-Meier
Centros de Atenção Terciária
Hepatectomia/efeitos adversos
Hepatectomia/mortalidade
Neoplasias Hepáticas/etiologia
Estadiamento de Neoplasias
Antineoplásicos/efeitos adversos
Limites: Humanos
Responsável: BR1.1 - BIREME


  4 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Mattos, Angelo Alves de
Texto completo
Id: biblio-887231
Autor: Branco, Fernanda; Alencar, Regiane S. M; Volt, Fernanda; Sartori, Giovana; Dode, Andressa; Kikuchi, Luciana; Tani, Claudia M; Chagas, Aline L; Pfiffer, Tulio; Hoff, Paulo; Carrilho, Flair J; Mattos, Angelo Alves de.
Título: The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
Fonte: Ann. hepatol;16(2):263-268, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background and Aims. The presence of dermatologic reaction as an adverse event to sorafenib treatment in patients with unresectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective analysis. To date, this is the only clinical predictor of treatment response, which can be evaluated earlier in the treatment and, therefore, contribute to a better and more individualized patient management. Material and methods. This retrospective study included 127 patients treated with sorafenib under real-life practice conditions in two hepatology reference centers in Brazil. Demographic data, disease/medical history and time of sorafenib administration as well as adverse events related to the medication were recorded in a database. Results. Cirrhosis was present in 94% of patients, 85.6% were Child-Pugh A, 80.3%BCLC-C, 81% had vascular invasion and/or extrahepatic spread and 95% had a performance status 0 to 1.The median duration of treatment was 10.1 months (range: 0.1-47 months).The most common adverse event within the first 60 days of treatment were diarrhea (62.2%) and dermatological reaction (42%).The median overall survival for the cohort was 20 months, and it was higher for patients who developed dermatological reactions within the first 60 days compared to those who did not present this adverse event. Conclusion. This retrospective analysis showed the use of sorafenib in patients selected according to BCLC staging, and it is the first external validation of early dermatologic adverse events as a predictor of overall survival in patients with advanced hepatocellular carcinoma.
Descritores: Compostos de Fenilureia/efeitos adversos
Niacinamida/análogos & derivados
Erupção por Droga/etiologia
Carcinoma Hepatocelular/tratamento farmacológico
Neoplasias Hepáticas/tratamento farmacológico
Antineoplásicos/efeitos adversos
-Fatores de Tempo
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Niacinamida/efeitos adversos
Erupção por Droga/diagnóstico
Erupção por Droga/mortalidade
Carcinoma Hepatocelular/mortalidade
Carcinoma Hepatocelular/patologia
Estimativa de Kaplan-Meier
Sorafenibe
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/patologia
Estadiamento de Neoplasias
Limites: Humanos
Responsável: BR1.1 - BIREME


  5 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1011433
Autor: Isah, Tasiu.
Título: De novo in vitro shoot morphogenesis from shoot tip-induced callus cultures of Gymnema sylvestre (Retz.) R. Br. ex Sm
Fonte: Biol. Res;52:3, 2019. tab, graf.
Idioma: en.
Resumo: BACKGROUND: Gymnema sylvestre is a medicinal woody perennial vine known for its sweetening properties and antidiabetic therapeutic uses in the modern and traditional medicines. Its over-exploitation for the therapeutic uses and to meet the demand of pharmaceutical industry in raw materials supply for the production of anti-diabetic drugs has led to considerable decline in its natural population. RESULTS: An efficient system of shoot bud sprouting from nodal segment explants and indirect plant regeneration from apical meristem-induced callus cultures of G. sylvestre have been developed on Murashige and Skoog (MS) medium amended with concentrations of cytokinins. Of the three growth regulators tested, N6-benzylaminopurine (BAP) was the most efficient and 2.0 mg L-1 gave the best shoot formation efficiency. This was followed by thidiazuron (TDZ) and kinetin (Kin) but, most of the TDZ-induced micro shoots showed stunted growth. Multiple shoot formation was observed on medium amended with BAP or TDZ at higher concentrations. The produced micro shoots were rooted on half strength MS medium amended with auxins and rooted plantlets acclimatized with 87% survival of the regenerates. CONCLUSIONS: The developed regeneration system can be exploited for genetic transformation studies, particularly when aimed at producing its high yielding cell lines for the anti-diabetic phytochemicals. It also offers opportunities for exploring the expression of totipotency in the anti-diabetic perennial vine.
Descritores: Reguladores de Crescimento de Plantas/farmacologia
Regeneração/efeitos dos fármacos
Brotos de Planta/crescimento & desenvolvimento
Gymnema sylvestre/crescimento & desenvolvimento
Morfogênese/efeitos dos fármacos
-Compostos de Fenilureia/farmacologia
Purinas/farmacologia
Tiadiazóis/farmacologia
Compostos de Benzil/farmacologia
Brotos de Planta/efeitos dos fármacos
Gymnema sylvestre/efeitos dos fármacos
Cinetina/farmacologia
Responsável: CL1.1 - Biblioteca Central


  6 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1053457
Autor: Suwanseree, Valerie; Phansiri, Salak; Yapwattanaphun, Chinawat.
Título: A comparison of callus induction in 4 Garcinia species
Fonte: Electron. j. biotechnol;40:45-51, July. 2019. ilus, tab.
Idioma: en.
Resumo: Background: This research is intended to determine suitable types and concentrations of plant growth regulators (PGRs) to induce callus on stem and leaf sections of 4 species of the genus Garcinia, namely, Garcinia mangostana, Garcinia schomburgkiana, Garcinia cowa, and Garcinia celebica. The base medium was MS medium containing 30 g l -1 sucrose, 0.5 g l-1 polyvinylpyrrolidone (PVP), and 7 g l-1 agar, and for the different treatments, PGRs were added to the medium as follows: thidiazuron (TDZ) at concentrations of 0, 0.1, 0.5, 1, and 2 mg l-1; 6-(3- hydroxybenzylamino) purine (meta-topolin) at concentrations of 0, 0.5, 2.5, and 5 mg l-1; 4-amino-3,5,6- trichloro-2-pyridinecarboxylic acid (picloram) at concentrations of 0, 0.5, 2.5, and 5 mg l-1; and 2,4- dichlorophenoxyacetic acid (2,4-D) at concentrations of 0, 0.5, 1, 2, and 4 mg l-1. The occurrence of callus was observed after 4 weeks. Results: A maximum of 100% and 93% of G. mangostana leaf explants formed callus in the 0.5 mg l-1 and 1 mg l-1 TDZ treatments, respectively, while 100% of G. schomburgkiana stem explants formed callus in the 1 mg l-1 TDZ treatment and 89% of G. schomburgkiana leaf explants formed callus in the 0.5 mg l-1 picloram treatment. The highest callus induction rate for G. cowa was 62% in the 1 mg l-1 TDZ treatment and for G. celebica was 56% in the 0.5 mg l-1•mT-1 treatment. Conclusions: For all 4 species, the greatest amount of large nodular callus was observed in the TDZ treatments. White, friable callus was observed on most of the 2,4-D and picloram treatment groups. Most meta-topolin treatments resulted in minimal callus formation.
Descritores: Reguladores de Crescimento de Plantas/metabolismo
Garcinia/crescimento & desenvolvimento
Compostos Fitoquímicos/metabolismo
-Compostos de Fenilureia
Tiadiazóis
Fatores de Tempo
Transformação Genética
Clusiaceae/crescimento & desenvolvimento
Garcinia/fisiologia
Técnicas de Cultura de Tecidos
Responsável: CL1.1 - Biblioteca Central


  7 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-757374
Autor: Pitoia, Fabián; Abelleira, Erika; Jerkovich, Fernando; Urciuoli, Carolina; Cross, Graciela.
Título: Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer
Fonte: Arch. endocrinol. metab. (Online);59(4):347-350, Aug. 2015. tab, ilus.
Idioma: en.
Resumo: Advanced radioactive refractory and progressive or symptomatic differentiated thyroid carcinoma (DTC) is a rare condition. Sorafenib was recently approved for the treatment of these patients. We present the case of a 67 year old woman diagnosed with DTC who underwent a total thyroidectomy with central, lateral-compartment neck dissection and shaving of the trachea and esophagus due to tumor infiltration. A local recurrence was detected 14 months later requiring, additionally, two tracheal rings resection. The patient received a cumulative 131I dose of 650 mCi and developed dysphagia and dyspnea 63 months after initial surgery. A 18FGD-PET/CT showed progression of the local mass associated to hypermetabolic pulmonary nodules. Sorafenib 800 mg/day was then prescribed. A dose reduction to 400 mg/day was necessary due to grade 3 thrombocytopenia that appeared four months after drug prescription. Platelet count went to normal after this dose reduction. Five months after initiation of sorafenib, a partial response of the local mass with significant intra-tumoral necrosis was observed. We conclude that sorafenib is a valid option for locally advanced DTC and that the platelet count should be evaluated regularly because it seems that thrombocytopenia might be more frequently observed in DTC than in other types of tumors.
Descritores: Compostos de Fenilureia/uso terapêutico
Trombocitopenia/induzido quimicamente
Neoplasias da Glândula Tireoide/terapia
Niacinamida/análogos & derivados
Recidiva Local de Neoplasia/terapia
Antineoplásicos/uso terapêutico
-Compostos de Fenilureia/administração & dosagem
Tireoidectomia
Neoplasias da Glândula Tireoide/complicações
Niacinamida/administração & dosagem
Niacinamida/uso terapêutico
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
Sorafenibe
Estadiamento de Neoplasias
Antineoplásicos/administração & dosagem
Limites: Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  8 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-950060
Autor: Danilovic, Debora L S; Castro Jr, Gilberto; Roitberg, Felipe S R; Vanderlei, Felipe A B; Bonani, Fernanda A; Freitas, Ricardo M C; Coura-Filho, George B; Camargo, Rosalinda Y; Kulcsar, Marco A; Marui, Suemi; Hoff, Ana O.
Título: Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
Fonte: Arch. endocrinol. metab. (Online);62(3):370-375, May-June 2018. graf.
Idioma: en.
Resumo: Summary Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.
Descritores: Compostos de Fenilureia/administração & dosagem
Neoplasias da Glândula Tireoide/terapia
Carcinoma Papilar/terapia
Niacinamida/análogos & derivados
Radioisótopos do Iodo/administração & dosagem
Antineoplásicos/administração & dosagem
-Tireoidectomia
Neoplasias da Glândula Tireoide/diagnóstico por imagem
Carcinoma Papilar/diagnóstico por imagem
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Niacinamida/administração & dosagem
Terapia Neoadjuvante
Sorafenibe
Câncer Papilífero da Tireoide
Limites: Humanos
Masculino
Adulto Jovem
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  9 / 24 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-983805
Autor: Pitoia, Fabián; Schmidt, Angélica; Bueno, Fernanda; Abelleira, Erika; Jerkovich, Fernando.
Título: Rare complications of multikinase inhibitor treatment
Fonte: Arch. endocrinol. metab. (Online);62(6):636-640, Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital. Subjects and methods: Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3.8%) received treatment with MKIs. The median age at diagnosis of these patients was 53 years (range 20-70), and 75.9% of them were women. Sorafenib was prescribed as first-line treatment to 23 patients with differentiated thyroid cancer and as second-line treatment to one patient with advanced medullary thyroid cancer (MTC). Vandetanib was indicated as first-line treatment in 6 patients with MTC and lenvatinib as second-line treatment in two patients with progressive disease under sorafenib treatment. Results: During the follow-up of treatment (mean 13.7 ± 7 months, median 12 months, range 6-32), 5/29 (17.2%) patients presented rare adverse events. These rare adverse effects were: heart failure, thrombocytopenia, and squamous cell carcinoma during sorafenib therapy and squamous cell carcinoma and oophoritis with intestinal perforation during vandetanib treatment. Conclusions: About 3 to 5 years after the approval of MKI therapy, we learned that MKIs usually lead to adverse effects in the majority of patients. Although most of them are manageable, we still need to be aware of potentially serious and rare or unreported adverse effects that can be life-threatening.
Descritores: Piperidinas/efeitos adversos
Quinazolinas/efeitos adversos
Carcinoma/tratamento farmacológico
Carcinoma Medular/tratamento farmacológico
Inibidores de Proteínas Quinases/efeitos adversos
Antineoplásicos/efeitos adversos
-Ooforite/induzido quimicamente
Compostos de Fenilureia/efeitos adversos
Quinolinas/efeitos adversos
Trombocitopenia/induzido quimicamente
Fatores de Tempo
Neoplasias da Glândula Tireoide/tratamento farmacológico
Estudos Retrospectivos
Fatores de Risco
Seguimentos
Estimativa de Kaplan-Meier
Sorafenibe/efeitos adversos
Insuficiência Cardíaca/induzido quimicamente
Perfuração Intestinal/induzido quimicamente
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Responsável: BR1.1 - BIREME


  10 / 24 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-777530
Autor: Gaudêncio, Fabrício Nascimento; Tunholi-Alves, Vinícius Menezes; Lima, Mariana Gomes; Gôlo, Patrícia Silva; Angelo, Isabele da Costa; Castro, Rosane Nora; Fonseca, Adivaldo Henrique da; Scott, Fabio Barbour; Pinheiro, Jairo.
Título: Alterations in the oxidative metabolism of Rhipicephalus (Boophilus) microplus ticks in response to exposure to the insect growth regulator fluazuron / Alterações no metabolismo oxidativo de carrapatos Rhipicephalus (Boophilus) microplus em resposta à exposição ao regulador de crescimento fluazuron
Fonte: Rev. bras. parasitol. vet;25(1):54-60, Jan.-Mar. 2016. graf.
Idioma: en.
Projeto: FAPERJ; . CNPq.
Resumo: Abstract Aiming to characterize the potential off-target effects of fluazuron on ticks, biochemical analyses were conducted to evaluate changes in the carbohydrate metabolism of Rhipicephalus (Boophilus) microplus ticks after exposure to fluazuron. Hemolymph and fat body were collected from female ticks before and after (4, 8 and 15 days) exposure to fluazuron. Spectrophotometric analyses were done to quantify glucose concentration and lactate dehydrogenase (LDH) activity in the hemolymph and the concentration of glycogen in the tick’s fat body. High Performance Liquid Chromatography (HPLC) was employed to determine the concentration of carboxylic acids in the hemolymph and to evaluate changes in intermediary metabolic processes requiring oxygen consumption. Increases in the levels of LDH activity and lactic acid concentration indicated that fluazuron enhanced fermentative metabolism in ticks. Exposure to fluazuron was also found to increase glucose concentrations in the hemolymph over time, although no significant differences were noted daily. In addition to expanding the body of knowledge about the mode of action of fluazuron, investigations into these mechanisms may also be useful in discovering new and as yet unexplored secondary effects.

Resumo Com o objetivo de caracterizar os efeitos não-alvo da ação do fluazuron, foram realizados testes bioquímicos para analisar possíveis alterações no metabolismo de carboidratos em carrapatos Rhipicephalus (Boophilus) microplus após sua exposição ao composto. Foram coletados hemolinfa e corpo gorduroso de fêmeas ingurgitadas antes e após (4, 8 e 15 dias) a exposição ao fluazuron. Análises espectrofotométricas foram usadas para quantificar a concentração de glicose e a atividade da lactato desidrogenase (LDH) na hemolinfa e concentração de glicogênio no corpo gorduroso. Cromatografia Líquida de Alta Eficiência (CLAE) foi usada para determinação das concentrações de ácidos carboxílicos na hemolinfa e avaliar possíveis alterações em metabolismo intermediário em relação ao consumo de oxigênio. Aumento na atividade de LDH e concentração de ácido lático indicaram que o fluazuron pode regular o metabolismo fermentativo em carrapatos. A exposição ao fluazuron também aumentou a concentração de glicose na hemolinfa, apesar de não ter havido diferença significativa na comparação entre as médias no mesmo dia de avaliação. Além de aumentar o conhecimento sobre o modo de ação do fluazuron, investigações sobre tais mecanismos também são úteis no descobrimento de novos efeitos secundários ainda não explorados.
Descritores: Compostos de Fenilureia/farmacologia
Corpo Adiposo/efeitos dos fármacos
Hemolinfa/efeitos dos fármacos
Rhipicephalus/efeitos dos fármacos
-Corpo Adiposo/química
Hemolinfa/química
Rhipicephalus/metabolismo
Limites: Animais
Feminino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde